ERBB2 and breast carcinoma: The APHINITY trial was conducted among node-positive or high-risk node-negative HER2 positive breast cancer women by comparing pertuzumab + trastuzumab with placebo + trastuzumab, and the incidence of primary cardiac events were 0.7% and 0.3 %, respectively, whereas the rate of decrease in LVEF is 0.6% and 0.2% [54].